NCT01971593View on ClinicalTrials.gov

The Effects of Eplerenone on Markers of Myocardial Fibrosis in Adult Congenital Heart Disease

PHASE4TerminatedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

March 31, 2016

Study Completion Date

June 30, 2016

Conditions
Tetralogy of FallotTransposition of the Great Vessels With an Arterial SwitchSingle Ventricle With a Fontan Palliation
Interventions
DRUG

Eplerenone

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Washington University School of Medicine

OTHER

NCT01971593 - The Effects of Eplerenone on Markers of Myocardial Fibrosis in Adult Congenital Heart Disease | Biotech Hunter | Biotech Hunter